Small Molecules

20 Mar 2017 Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
20 Mar 2017 Opiant Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
20 Mar 2017 Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
20 Mar 2017 Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases
20 Mar 2017 Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival
20 Mar 2017 AstraZeneca’s CVD-REAL study shows SGLT-2 inhibitors significantly reduced death and hospitalisations for heart failure versus other type-2 diabetes medicines
20 Mar 2017 Bayer’s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
17 Mar 2017 First dedicated outcome trials of empagliflozin in chronic heart failure initiated
17 Mar 2017 Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
17 Mar 2017 AstraZeneca receives Complete Response Letter from US FDA for ZS-9 (sodium zirconium cyclosilicate) for hyperkalaemia
16 Mar 2017 Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis
16 Mar 2017 Asana BioSciences Announces FDA Acceptance of the IND Application for its Novel SYK-JAK Inhibitor for Evaluation in Atopic Dermatitis
15 Mar 2017 Vtesse Completes Enrollment of Phase 2b/3 Pivotal Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease
15 Mar 2017 Catalyst Pharmaceuticals Announces Positive Data from Investigator-Sponsored Trial of Firdapse(R) in treating MuSK Antibody Positive Myasthenia Gravis
15 Mar 2017 Lynparza Phase III SOLO-2 data demonstrate progression-free survival benefit in BRCA-mutated ovarian cancer as maintenance therapy
14 Mar 2017 MetrioPharm Announces Positive Top-Line Results from a Phase IIa Study in Moderate-to-Severe Psoriasis with its Oral Lead Compound MP1032
14 Mar 2017 twoXAR Announces Preclinical Proof-of-Concept Data on Novel Liver Cancer Candidate
14 Mar 2017 LSK BioPharma Announces Enrollment of First Patient in Phase 3 Apatinib Trial in Gastric Cancer
14 Mar 2017 Sunovion Submits Supplemental New Drug Application to FDA for Use of APTIOM® (eslicarbazepine acetate) for the Treatment of Partial-Onset Seizures in Children 4 Years of Age and Older
14 Mar 2017 Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
13 Mar 2017 Clovis Oncology Presents New Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer at 2017 SGO Annual Meeting on Women’s Cancer
13 Mar 2017 Karyopharm Announces Partial Clinical Hold to Pause Enrollment in Selinexor Trials
12 Mar 2017 BeiGene Announces Initiation of Pivotal Study in China with BTK Inhibitor BGB-3111 in Patients with Relapsed or Refractory CLL/SLL
12 Mar 2017 New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease
09 Mar 2017 Tyrogenex Completes Patient Enrollment in its Phase 2 Trial of Orally Administered Vorolanib for Wet Age-related Macular Degeneration

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing